{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:05:00Z","timestamp":1789833900875,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007288","name":"Mahasarakham University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.vhri.2026.101692","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:42:23Z","timestamp":1787139743000},"page":"101692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness of Ribociclib Plus Endocrine Therapy for Premenopausal or Perimenopausal Women With Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Thailand"],"prefix":"10.1016","volume":"58","author":[{"given":"Surachai","family":"Sittibodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onanong","family":"Waleekhachonloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thananan","family":"Rattanachotphanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vhri.2026.101692_bib1","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1634\/theoncologist.2019-0729","article-title":"Hormone receptor-positive\/human epidermal growth receptor 2-negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents","volume":"25","author":"Shah","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.vhri.2026.101692_bib4","series-title":"Guidelines for Reimbursement of Health Services for Adult Cancer [in Thai]","first-page":"5","article-title":"Breast cancer","year":"2023"},{"issue":"7","key":"10.1016\/j.vhri.2026.101692_bib6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.vhri.2026.101692_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- Advanced Breast Cancer in MONALEESA-7: a Phase III Randomized Clinical Trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.vhri.2026.101692_bib8","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.clbc.2021.01.019","article-title":"First-line treatment with ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive advanced breast cancer: a cost-effectiveness analysis","volume":"21","author":"Huang","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.vhri.2026.101692_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658054","article-title":"Cost-effectiveness of adding ribociclib to endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer among premenopausal or perimenopausal women","volume":"11","author":"Jeong","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2026.101692_bib10","first-page":"327","article-title":"Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer","volume":"27","author":"Le","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.vhri.2026.101692_bib11","article-title":"Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore","volume":"4","author":"Loke","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.vhri.2026.101692_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221100865","article-title":"Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+\/HER2- advanced breast cancer: a Brazilian public health care system perspective","volume":"14","author":"Rosa","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.vhri.2026.101692_bib13","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jval.2023.09.352","article-title":"EE80 Cost-effectiveness of ribociclib plus a non-steroidal aromatase inhibitor for the treatment of pre- and perimenopausal women with HR+\/HER2\u2212 advanced breast cancer in Turkey","volume":"26","author":"Tatar","year":"2023","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2026.101692_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40273-021-01028-3","article-title":"Cost effectiveness of ribociclib plus a nonsteroidal aromatase inhibitor in pre-\/perimenopausal, HR+ and HER2\u2212 advanced breast cancer: a Canadian healthcare perspective","volume":"39","author":"Stellato","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.vhri.2026.101692_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"26","key":"10.1016\/j.vhri.2026.101692_bib17","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vhri.2026.101692_bib18","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/annonc\/mdt065","article-title":"A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer: CYCLOX II","volume":"24","author":"Harvey","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vhri.2026.101692_bib20","series-title":"Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal","year":"2010"},{"key":"10.1016\/j.vhri.2026.101692_bib22","first-page":"1307","article-title":"Management strategies and outcomes in HR+\/HER2- Metastatic Breast Cancer Receiving CDK4\/6 Inhibitors and Subsequent Therapies","volume":"17","author":"Pogoda","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.vhri.2026.101692_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2022.09.005","article-title":"Concept: a randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer","volume":"66","author":"Bahl","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.vhri.2026.101692_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/2193-1801-3-259","article-title":"Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens","volume":"3","author":"Hansen","year":"2014","journal-title":"Springerplus"},{"issue":"5","key":"10.1016\/j.vhri.2026.101692_bib25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/0284186X.2017.1400683","article-title":"Health-related quality of life in different states of breast cancer\u2014comparing different instruments","volume":"57","author":"Rautalin","year":"2018","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.vhri.2026.101692_bib26","first-page":"514","article-title":"Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+\/HER2- Advanced or Metastatic Breast Cancer: a U.S. Payer Perspective","volume":"24","author":"Mistry","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.vhri.2026.101692_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40273-022-01232-9","article-title":"Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment","volume":"41","author":"Lu","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2026.101692_bib29","first-page":"959","article-title":"Cost of palliative care in advanced cancer at Trat Hospital","volume":"15","author":"Apiwat","year":"2023","journal-title":"Thai J Pharm Pract"},{"issue":"5","key":"10.1016\/j.vhri.2026.101692_bib30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14737167.2018.1494574","article-title":"The EQ-5D-5L valuation study in Thailand","volume":"18","author":"Pattanaphesaj","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2026.101692_bib31","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1186\/s12885-024-12765-x","article-title":"Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR+\/HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand","volume":"24","author":"Dajsakdipon","year":"2024","journal-title":"BMC Cancer"},{"issue":"Suppl 5","key":"10.1016\/j.vhri.2026.101692_bib32","first-page":"S127","article-title":"Standard cost lists for health economic evaluation in Thailand","volume":"97","author":"Riewpaiboon","year":"2014","journal-title":"J Med Assoc Thai"},{"issue":"Suppl 6","key":"10.1016\/j.vhri.2026.101692_bib33","article-title":"47MO Efficacy and quality of life in premenopausal Asian patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in the MONALEESA-7 study","volume":"31","author":"Lu","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.vhri.2026.101692_bib34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.vhri.2026.101692_bib35","first-page":"39","article-title":"A method of deriving estimates of health state utilities for patients with metastatic breast cancer","volume":"2","author":"Hudgens","year":"2016","journal-title":"J Clin Pathw"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992600107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992600107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:55:05Z","timestamp":1789833305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992600107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":28,"alternative-id":["S221210992600107X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101692","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Ribociclib Plus Endocrine Therapy for Premenopausal or Perimenopausal Women With Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Thailand","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101692"}}